【WO2019196965A2】一种治疗恶性黑色素瘤的药物制剂【专利】

)

(

(51)International Patent Classification:

A61K 31/404(2006.01)A61K 31/519(2006.01)

Declarations under Rule 4.17:A61K 31/426(2006.01)A61K 31/551(2006.01)

—as to the identity o f the inventor (Rule 4.17(i))A61K 31/496(2006.01)A61P 35/00(2006.01)

—as to applicant's entitlement to apply for and be granted a A61K 31/506(2006.01)

patent (Rule 4.17(H))(21)International Application Number:

Published:PCT/CZ2019/000018

—without international search report and to be republished upon receipt o f that report (Rule 48.2(g))

(22)International Filing Date:

10April 2019(10.04.2019)(25)Filing Language:

English (26)Publication Language:

English (30)Priority Data:

PV 2018-18111April 2018(11.04.2018)

CZ (71)Applicant:UNIVERZITA KARLOVA [CZ/CZ];Ovoc-

ny trh 560/5,CZ-11636Praha 1(CZ).

(72)Inventor:VACHTENHEIM,Jiri;Janskeho 2233/57,

CZ-15500Praha (CZ).

(74)Agent:GUTTMANN,Michal et al.;Rott,Ruzicka &

Guttmann a spol.,Vyskocilova 1566,14000Praha 4(CZ).

(81)Designated States (unless otherwise indicated,for every

kind o f national protection available):AE,AG,AL,AM,

AO,AT,AU,AZ,BA,BB,BG,BH,BN,BR,BW,BY,BZ,

CA,CH,CL,CN,CO,CR,CU,CZ,DE,DJ,DK,DM,DO,

DZ,EC,EE,EG,ES,FI,GB,GD,GE,GH,GM,GT,HN,

HR,HU,ID,IL,IN,IR,IS,JO,JP,KE,KG,KH,KN,KP,

KR,KW,KZ,LA,LC,LK,LR,LS,LU,LY,MA,MD,ME,

MG,MK,MN,MW,MX,MY,MZ,NA,NG,NI,NO,NZ,

OM,PA,PE,PG,PH,PL,PT,QA,RO,RS,RU,RW,SA,

SC,SD,SE,SG,SK,SL,SM,ST,SV,SY,TH,TJ,TM,TN,

TR,TT,TZ,UA,UG,US,UZ,VC,VN,ZA,ZM,ZW.

(84)Designated States (unless otherwise indicated,for every

kind o f regional protection available):ARIPO (BW,GH,

GM,KE,LR,LS,MW,MZ,NA,RW,SD,SL,ST,SZ,TZ,

UG,ZM,ZW),Eurasian (AM,AZ,BY,KG,KZ,RU,TJ,

TM),European (AL,AT,BE,BG,CH,CY,CZ,DE,DK,

EE,ES,FI,FR,GB,GR,HR,HU,IE,IS,IT,LT,LU,LV,

MC,MK,MT,NL,NO,PL,PT,RO,RS,SE,SI,SK,SM,

TR),OAPI (BF,BJ,CF,CG,Cl,CM,GA,GN,GQ,GW,

KM,ML,MR,NE,SN,TD,TG).

(54)Title:PHARMACY PREPARATION FOR MALIGNANT MELANOMA TREATMENT

(57)Abstract:The invention relates to a pharmacy preparation for malignant melanoma treatment containing combination of active ingredients,being GANT61,Obatoclax with the advantage of its mesylate salt,and agent selected from the group comprising (+)-JQ1,SGI-7079,GSK343,GSK126,HA15,wherein concentration of active ingredients in the specific triple-combination necessary to eradicate tumor cells is as follows:a)GANT61from 10to 20pmol/l;b)Obatoclax from 150to 300nmol/1;cl)(+)-JQ 1from 125to 500nmol/1;c2)SGI-7079from 125to 500nmol/1;c3)GSK343from 0.25to 1,0pmol/l;c4)GSK126from 25to 100nmol/1;and c5)HA15from 2.5to 10pmol/l.All triple-combinations are highly effective in the experiments carried-out on cell cultures of human melanoma cells,when all tumor cells were eradicated not later than 7th day after application.